{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"361"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant administered a study treatment and did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Per protocol, only data generated during the initial course of treatment contributed to the analysis.","groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 2 years. Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to an additional year.","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one dose of study treatment during the initial course of treatment","reportingStatus":"POSTED","timeFrame":"Up to approximately 80.5 months","title":"Number of Participants Who Experienced At Least One Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Participants"}